Denali Therapeutics Inc. announced that its partner Sanofi has commenced dosing in a Phase 2 study of SAR443820 (DNL788) in individuals with multiple sclerosis. SAR443820 is a central nervous system (CNS)-penetrant investigational small molecule inhibitor of RIPK1. Sanofi is also conducting two Phase 2 clinical studies with another RIPK1 inhibitor, SAR443122 (eclitasertib; DNL758), in cutaneous lupus erythematosus and ulcerative colitis.

SAR443122 (eclitasertib) is a peripherally restricted RIPK1 inhibitor and was discovered by Denali scientists. Sanofi is responsible for the development and commercialization of SAR443122 (eclitasertib) and covers all costs related to the program. Denali is entitled to receive development, regulatory and sales milestone payments and royalties on product sales.

SAR443820 and SAR443122 (eclitasertib) are investigational therapeutics that have not been approved by any regulatory authority for any commercial use.